Alexion reports revamped Irish tax structure; UCB to market Biogen Idec drugs in Asia; Celgene's Revlimid sales jump 13%;

@FiercePharma: Lilly surprises on revenue even as Cymbalta sinks. Story | Follow @FiercePharma

@TracyStaton: BMS counts on DTC to keep driving Eliquis growth. But are its ads much different from rivals? News | Follow @TracyStaton

@EricPFierce: Lilly announced 1,000 job cuts in 2013. 2014 expected to be even bleaker. Report | Follow @EricPFierce

@CarlyHFierce: Vertex profits on one-time gain despite plummeting Incivek sales. Item | Follow @CarlyHFierce

> Shares of Alexion ($ALXN) soared 21% after the rare-disease drugmaker reported earnings and announced an Irish tax restructuring that will drive profitability. Report

> Sales of Celgene's ($CELG) blood cancer drug Revlimid rose 13% in the fourth quarter to $1.14 billion. Report (sub. req.)

> AstraZeneca ($AZN) is shuttering an R&D facility in Bangalore, India, cutting 168 jobs as it works through its global R&D restructuring. Story

> India's Cadila Healthcare has received FDA approval to market its Etodolac extended release arthritis treatment in the U.S. Report

> Biogen Idec ($BIIB) and Belgium's UCB have entered an agreement to commercialize multiple sclerosis and hemophilia treatments in Asia. More

> India's Competition Commission has given the green light to KKR's proposed purchase of a minority stake in Gland Pharma. News

Medical Device News

@FierceMedDev:Zimmer finishes 2013 with a leg up from new products. Story | Follow @FierceMedDev

@MarkHFierce: Medtronic is shifting its Middle East HQ from Lebanon to Dubai. More growth opportunities and investment $ to tap. Story via The National | Follow @MarkHFierce

@GalenMoore: This may be the year Valeant writes the check that vaults it into the top tier of drugmakers. Story via Bloomberg | Follow @GalenMoore

@MichaelGFierce: Nanogold 'superstructures' are held together with DNA for #cancer drug delivery. Story from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: NeoGenomics launches 22 cancer profiling tests. Article | Follow @EmilyWFierce

> Medtronic leads in FDA Class I recalls for 2013. Story

> Quest's Q4 revenue dipped, but CEO Rusckowski insists changes yielded progress. More

Biotech News

@FierceBiotech: Wilex cuts 80% of its staff as it pulls the plug on a once-promising cancer therapy. More | Follow @FierceBiotech

@JohnCFierce: Aveo now can't even recruit patients for a trial? They might want to consider a new biz model--outside of biotech. Release | Follow @JohnCFierce

@DamianFierce: KaloBios calls it quits on its asthma drug after a Phase II flop. Story | Follow @DamianFierce

@EmilyMFierce: J&J enlists Yale to oversee clinical trials data sharing. News | Follow @EmilyMFierce

> Progenics tanks after two trial deaths cast doubt on its lead program. Article

> Despite a years-long dry run, Lilly keeps the faith in its pipeline. Read

Pharma Manufacturing News

> India's top drug regulator says he will do surprise inspections of foreign-owned plants. Story

> Novartis' production reduction plan has shed 20 plants in 4 years. Article

> Flu hospitalizations are putting pressure on saline manufacturers in face of shortage. Item

> Amgen confirms the $1B Ireland plant it postponed 7 years ago will not get built. Story

> Cytovance expands its biologics manufacturing and warehousing operations. News

> DOJ says to expect consent decrees like the one Ranbaxy signed as its tool of choice. Article

Vaccines News

> Survey: Anti-vaccine views have little correlation with politics. Story

> The NIH is infecting volunteers with flu to find out how the immune system works. News

> Production problem prompts GSK to stop worldwide deliveries of chickenpox vaccines. Article

> The U.K. is set to fall well short of flu vaccine uptake targets. Story

> Pfizer pins hopes on vaccine data to kick-start revenue growth. Story

> Novartis: We cannot keep shipping Bexsero under an investigational license. Item

And Finally... A new study says obesity gains its hold in a child's early years; a third of overweight kindergartners who participated were obese by 8th grade, it says. Story (sub. req.)

Suggested Articles

Download our solutions overview to discover how CoverMyMeds can make a difference for your brand.

In a bladder cancer field chock-full of checkpoint inhibitors, Pfizer and Merck KGaA’s Bavencio has a chance to get ahead thanks to new data.

The FDA backtracked on its earlier testing and found NDMA contamination in the extended release formulation of certain generic versions of metformin.